Stocks to watch today: HDFC, Sun Pharma, and Cipla will report their June quarter results on Friday, July 29; Dr Reddy's saw 108 per cent YoY rise in consolidated net profit to Rs 1,187.6 crore in Q1.
The DRL stock was down marginally (0.73 per cent) to Rs 4,254 on the BSE on Thursday
CLOSING BELL: Tata Steel, Kotak Bank, IndusInd Bank, Nestle, Infosys, Asian Paints, and Tech M were the other outperformers, up between 3 per cent and 4.6 per cent
Stocks to watch today: Dr Reddy's, Bajaj Finserv, Nestle India will report their June quarter results on Thursday, July 28; HAL signed $100 million contract with Honeywell for HTT-40 engines.
Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.
The company launched its generic version of fesoterodine fumarate extended-release tablets that can be used for treating overactive bladder in the US market.
CLOSING BELL: L&T, PowerGrid, NTPC, ICICI Bank, DR Reddy's Labs, Axis Bank, Bharti Airtel, and Nestle India were the top large-cap gainers
Stocks to watch today: IT behemoth Tata Consultancy Services (TCS) is slated to report June quarter 2022 numbers (Q1FY23); Dr Reddy's received two observations from USFDA for its Andhra plant
CLOSING BELL: It was, largely, a broad-based rally where the Nifty PSU Bank index advanced the most, up 3.4 per cent
Dr Reddy's Laboratories on Thursday said it has settled patent litigation with Indivior Inc and Aquestive Therapeutics on a medication used to treat opioid dependence or addiction
Under the terms of the agreement, Dr Reddy's acquired the Eton portfolio for an upfront payment of approximately USD 5 million in cash, besides contingent payments of up to USD 45 million
Dr Reddy's Laboratories on Thursday said its subsidiary has inked a pact with US-based Olema Pharmaceuticals Inc to research, develop and commercialise novel small molecule inhibitors of a target
The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).
Dr Reddy's Laboratories is hoping to go to a regulator for its single-dose Sputnik Light jab as booster dose for approvals by June-end or early July, a senior official said
Tech Mahindra and Wipro have tumbled over 30 per cent, while Apollo Hospitals Enterprise and Dr. Reddy's Laboratories have plummeted 22 per cent so far in calendar year 2022 (CY22)
Indian pharmaceutical major Dr. Reddy's Laboratories Ltd said on Wednesday it was focused on employee safety and business continuity in and around Russia
Closing Bell: The frontline S&P BSE Sensex fell 69 points to settle at 57,232 levels while the Nifty50 shut shop at 17,063 down 29 points
Mankind Pharma to take over manufacturing, marketing and distribution of both products in India; entire integration and transition of the brands likely to be completed by March
All the sectoral indices settled in the negative territory today with technology and public sector banks being the worst hit. The IT and PSB indices dropped nearly 3% and 2%, respectively
BPCL, DLF, Dwarikesh Sugar, Exide, GIC Housing, HDIL, HPCL, IOC, Jindal Saw, KEC Intl, KPIT Tech, Krsnaa Diagnostics, SCI, Sun Pharma, Suven Life, Tata Motors and UCO Bank in focus ahead of Q3 results